Objectives: To define the involvement of CALM and AF10 fusion transcripts in primary leukaemias with t(10; 11). Methods: The AF10 and CALM fusion in five t(10; 11) leukemia samples were checked by reverse transcriptas...Objectives: To define the involvement of CALM and AF10 fusion transcripts in primary leukaemias with t(10; 11). Methods: The AF10 and CALM fusion in five t(10; 11) leukemia samples were checked by reverse transcriptase-polymerase chain reaction (RT-PCR), and effects of CALM/AF10 antisense phosphorothioate oligodeoxynucleotides (AS PS-ODNs) on chemotherapy sensitivity and apoptosis of leukemia cells in vitro were observed. Results: Five different-sized AF10-CALM products and four different-sized CALM/AF10 products were detected by RT-PCR. The chemotherapy sensitivity of leukemic cells with t(10; 11) to drugs in vitro was lower than that of leukemic cells without t(10; 11). AS PS-ODNs increased the chemotherapy sensitivity and apoptotic rate. There were 4 cases positive at 5 μmol/L concentration, all cases positive at 10 μmol/L and 20 μmol/L concentration, P<0.01 vs only chemotherapeutic drugs (3 cases positive), and chemotherapeutic drugs + S-PS-ODNs (10 μmol/L) (3 cases positive). After cells were treated with 10 μmol/L AS-PS-ODNs + chemotherapeutic drugs for 48 h, 72 h, 96 h, the apoptotic indexes were 14.22±2.86, 29.39±3.57, and 41.26±4.52, respectively. These were significantly higher than those of only chemotherapeutic drugs-treated cells and chemotherapeutic drugs + S-PS-ODNs-treated cells at corresponding time (P<0.01). There was no difference between only drugs group and S-PS-ODNs group at corresponding time (P>0.05). Conclusion: The CALM and AF10 fusion transcripts are involved in the pathogenesis of haematological malignancies with t(10, 11), and is associated with a poor prognosis. AS-PS-ODNs might be useful in therapy of t(10, 11) leukemia. Key words AF10 - CALM - Fusion transcript - Primary leukemia cell - In vitro sensitivity - Antisense oligodeoxynucleotide CLC number R733.7 Biography: LIU Ge-xiu (1968–), male, associate professor, Institute of Hematology, Medical College, Jinan University, majors in hematology.展开更多
目的:通过大鼠下颌骨缺损再植的实验动物模型,基于Janus激酶-信号转导与转录激活因子(Janus kinase-signal transducers and activators of transcription,JAK-STAT)通路探讨注射重组人源肿瘤坏死因子受体融合蛋白(recombinant human tu...目的:通过大鼠下颌骨缺损再植的实验动物模型,基于Janus激酶-信号转导与转录激活因子(Janus kinase-signal transducers and activators of transcription,JAK-STAT)通路探讨注射重组人源肿瘤坏死因子受体融合蛋白(recombinant human tumor necrosis factor receptor:Fc fusion protein,rhTNFR:Fc)对下颌骨缺损大鼠的干预效果。方法:将70只(雌雄各半)7~8周龄的健康SD大鼠随机分为3组,分别为空白组(10只)、对照组(30只)和实验组(30只)。实验组:于大鼠骨缺损处注入含有Rh TNFR:Fc(45 mg/kg)的Bio-Oss骨颗粒,其上覆盖Bio-Gide胶原膜;对照组:于大鼠缺损处注入含25μL 0.9%氯化钠溶液的Bio-Oss骨颗粒,同样覆盖Bio-Gide胶原膜;空白对照组为健康大鼠。取所有大鼠下颌骨组织,观察其形态学变化,行组织形态计量学测定。实验组和对照组大鼠于术后3、6、9周时被分批处死,取其左侧下颌骨进行炎症因子白细胞介素-6(interleukin-6,IL-6)和肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)表达水平的检测,同时检测组织中凋亡相关分子Bax、Bcl-2、p-JAK2和p-STAT3蛋白的表达。结果:与对照组比较,实验组的缺损面积显著减少,IL-6和TNF-α的浓度显著下降,而凋亡相关分子Bax、p-JAK2和p-STAT3的表达显著下降,Bcl-2表达显著升高(P<0.05);与空白组比较,对照组和实验组缺损面积显著增加,缺损模型建立成功。结论:局部注射rh TNFR:Fc与Bio-Oss骨颗粒能够有效地促进下颌骨缺损修复,并且效果显著优于只使用Bio-Oss骨颗粒的组别,其修复作用与抑制细胞凋亡的能力相关,通过实验我们发现JAK2-STAT3细胞信号通路在其中发挥了重要作用。展开更多
文摘Objectives: To define the involvement of CALM and AF10 fusion transcripts in primary leukaemias with t(10; 11). Methods: The AF10 and CALM fusion in five t(10; 11) leukemia samples were checked by reverse transcriptase-polymerase chain reaction (RT-PCR), and effects of CALM/AF10 antisense phosphorothioate oligodeoxynucleotides (AS PS-ODNs) on chemotherapy sensitivity and apoptosis of leukemia cells in vitro were observed. Results: Five different-sized AF10-CALM products and four different-sized CALM/AF10 products were detected by RT-PCR. The chemotherapy sensitivity of leukemic cells with t(10; 11) to drugs in vitro was lower than that of leukemic cells without t(10; 11). AS PS-ODNs increased the chemotherapy sensitivity and apoptotic rate. There were 4 cases positive at 5 μmol/L concentration, all cases positive at 10 μmol/L and 20 μmol/L concentration, P<0.01 vs only chemotherapeutic drugs (3 cases positive), and chemotherapeutic drugs + S-PS-ODNs (10 μmol/L) (3 cases positive). After cells were treated with 10 μmol/L AS-PS-ODNs + chemotherapeutic drugs for 48 h, 72 h, 96 h, the apoptotic indexes were 14.22±2.86, 29.39±3.57, and 41.26±4.52, respectively. These were significantly higher than those of only chemotherapeutic drugs-treated cells and chemotherapeutic drugs + S-PS-ODNs-treated cells at corresponding time (P<0.01). There was no difference between only drugs group and S-PS-ODNs group at corresponding time (P>0.05). Conclusion: The CALM and AF10 fusion transcripts are involved in the pathogenesis of haematological malignancies with t(10, 11), and is associated with a poor prognosis. AS-PS-ODNs might be useful in therapy of t(10, 11) leukemia. Key words AF10 - CALM - Fusion transcript - Primary leukemia cell - In vitro sensitivity - Antisense oligodeoxynucleotide CLC number R733.7 Biography: LIU Ge-xiu (1968–), male, associate professor, Institute of Hematology, Medical College, Jinan University, majors in hematology.